Udskriv Udskriv
Switch language
Rigshospitalet - en del af Københavns Universitetshospital

Impact of Time to Treatment Initiation in Patients with Human Papillomavirus-positive and -negative Oropharyngeal Squamous Cell Carcinoma

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review


  1. Cutaneous Lymphomas

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Radiotherapy studies and extra-nodal non-Hodgkin lymphomas, progress and challenges

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Development of depression in patients with oral cavity cancer: a systematic review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  2. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Association between head and neck cancer and sexually transmitted diseases: a Danish nationwide, case-control study

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

AIMS: The distinct difference in disease phenotype of human papillomavirus-positive (HPV+) and -negative (HPV-) oropharyngeal squamous cell cancer (OPSCC) patients might also be apparent when assessing the effect of time to treatment initiation (TTI). We assessed the overall survival and progression-free survival (PFS) effect from increasing TTI for HPV+ and HPV- OPSCC patients.

MATERIALS AND METHODS: We examined patients who received curative-intended therapy for OPSCC in eastern Denmark between 2000 and 2014. TTI was the number of days from diagnosis to the initiation of curative treatment. Overall survival and PFS were measured from the start of treatment and estimated with the Kaplan-Meier estimator. Hazard ratios and 95% confidence intervals were estimated with Cox proportional hazard regression.

RESULTS: At a median follow-up of 3.6 years (interquartile range 1.86-6.07 years), 1177 patients were included (59% HPV+). In the adjusted analysis for the HPV+ and HPV- patient population, TTI influenced overall survival and PFS, most evident in the HPV- group, where TTI >60 days statistically significantly influenced overall survival but not PFS (overall survival: hazard ratio 1.60; 95% confidence interval 1.04-2.45; PFS: hazard ratio 1.46; 95% confidence interval 0.96-2.22). For patients with a TTI >60 days in the HPV+ group, TTI affected overall survival and PFS similarly, with slightly lower hazard ratio estimates of 1.44 (95% confidence interval 0.83-2.51) and 1.15 (95% confidence interval 0.70-1.88), respectively.

CONCLUSION: For patients treated for a HPV+ or HPV- OPSCC, TTI affects outcome, with the strongest effect for overall survival among HPV- patients. Reducing TTI is an important tool to improve the prognosis.

TidsskriftClinical oncology (Royal College of Radiologists (Great Britain))
Udgave nummer6
Sider (fra-til)375-381
Antal sider7
StatusUdgivet - jun. 2018

ID: 55218452